Cargando…

Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani

[Image: see text] Visceral leishmaniasis (VL), caused by the protozoan parasites Leishmania donovani and L. infantum, is responsible for ∼30 000 deaths annually. Available treatments are inadequate, and there is a pressing need for new therapeutics. N-Myristoyltransferase (NMT) remains one of the fe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Corpas-Lopez, Victoriano, Moniz, Sonia, Thomas, Michael, Wall, Richard J., Torrie, Leah S., Zander-Dinse, Dorothea, Tinti, Michele, Brand, Stephen, Stojanovski, Laste, Manthri, Sujatha, Hallyburton, Irene, Zuccotto, Fabio, Wyatt, Paul G., De Rycker, Manu, Horn, David, Ferguson, Michael A. J., Clos, Joachim, Read, Kevin D., Fairlamb, Alan H., Gilbert, Ian H., Wyllie, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332449/ https://www.ncbi.nlm.nih.gov/pubmed/30380837 http://dx.doi.org/10.1021/acsinfecdis.8b00226

Ejemplares similares

Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani
por: Torrie, Leah S., et al.
Publicado: (2017)

Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase
por: Roberts, Adam J., et al.
Publicado: (2014)

Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors
por: Brand, Stephen, et al.
Publicado: (2011)

The Q(i) Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani
por: Wall, Richard J., et al.
Publicado: (2020)

N-Myristoyltransferase inhibitors as new leads to treat sleeping sickness
por: Frearson, Julie A., et al.
Publicado: (2010)

Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors
por: Bayliss, Tracy, et al.
Publicado: (2017)

Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode
por: Spinks, Daniel, et al.
Publicado: (2015)

A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors
por: Harrison, Justin R., et al.
Publicado: (2018)

Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma bruceiN-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis
por: Brand, Stephen, et al.
Publicado: (2014)

Discovery of high affinity inhibitors of Leishmania donovani N-myristoyltransferase
por: Rackham, Mark D., et al.
Publicado: (2015)

Stage-specific expression of the mitochondrial co-chaperonin of Leishmania donovani, CPN10
por: Zamora-Veyl, Fanny Beatriz, et al.
Publicado: (2005)

Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity
por: Nühs, Andrea, et al.
Publicado: (2015)

The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis
por: Patterson, Stephen, et al.
Publicado: (2013)

Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis
por: Jones, Deuan C., et al.
Publicado: (2010)

Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase
por: Torrie, Leah S., et al.
Publicado: (2019)

N-Myristoyltransferase from Leishmania donovani: Structural and Functional Characterisation of a Potential Drug Target for Visceral Leishmaniasis
por: Brannigan, James A., et al.
Publicado: (2010)

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis
por: Thomas, Michael, et al.
Publicado: (2021)

Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static–Cidal Screening of Analogues
por: Cleghorn, Laura A. T., et al.
Publicado: (2023)

Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasis
por: Wyllie, Susan, et al.
Publicado: (2018)

Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas’ Disease
por: Lima, Marta L., et al.
Publicado: (2022)

Global Analysis of Protein N-Myristoylation and Exploration of N-Myristoyltransferase as a Drug Target in the Neglected Human Pathogen Leishmania donovani
por: Wright, Megan H., et al.
Publicado: (2015)

N-Myristoyltransferase Is a Cell Wall Target in Aspergillus fumigatus
por: Fang, Wenxia, et al.
Publicado: (2015)

Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei
por: Cleghorn, Laura A. T., et al.
Publicado: (2015)

Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity
por: Thomas, Michael G., et al.
Publicado: (2020)

Molecular Preadaptation to Antimony Resistance in Leishmania donovani on the Indian Subcontinent
por: Dumetz, F., et al.
Publicado: (2018)

Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library
por: Woodland, Andrew, et al.
Publicado: (2015)

Utilizing thermal proteome profiling to identify the molecular targets of anti-leishmanial compounds
por: Corpas-Lopez, Victoriano, et al.
Publicado: (2021)

The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis
por: Patterson, Stephen, et al.
Publicado: (2016)

Multiple unbiased approaches identify oxidosqualene cyclase as the molecular target of a promising anti-leishmanial
por: Paradela, Luciana S., et al.
Publicado: (2021)

Characterisation of a putative glutamate 5‐kinase from Leishmania donovani
por: Sienkiewicz, Natasha, et al.
Publicado: (2018)

Validation and Invalidation of Chemical Probes for the Human N-myristoyltransferases
por: Kallemeijn, Wouter W., et al.
Publicado: (2019)

The Leishmania donovani SENP Protease Is Required for SUMO Processing but Not for Viability
por: Bea, Annika, et al.
Publicado: (2020)

The role of N-myristoyltransferase 1 in tumour development
por: Wang, Hong, et al.
Publicado: (2023)

Trypanosoma cruzi Phosphomannomutase and Guanosine Diphosphate-Mannose Pyrophosphorylase Ligandability Assessment
por: Zmuda, Filip, et al.
Publicado: (2019)

Life Cycle Stage-Specific Accessibility of Leishmania donovani Chromatin at Transcription Start Regions
por: Grünebast, Janne, et al.
Publicado: (2021)

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition
por: Wyllie, Susan, et al.
Publicado: (2019)

Toolkit of Approaches To Support Target-Focused Drug Discovery for Plasmodium falciparum Lysyl tRNA Synthetase
por: Milne, Rachel, et al.
Publicado: (2022)

QSAR Study of N-Myristoyltransferase Inhibitors of Antimalarial Agents
por: Santos-Garcia, Letícia, et al.
Publicado: (2018)

A small heat shock protein is essential for thermotolerance and intracellular survival of Leishmania donovani
por: Hombach, Antje, et al.
Publicado: (2014)

Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi
por: Herrera, Linda J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cg8nr459kki2plj1rghqckkh2p